|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Več možnosti |
|
|
© 2024 SFX by Ex Libris Inc. | Piškotki
CrossRef Omogočeno
|